Gabriel Zarbiv

Gabriel Zarbiv, PhD has a diverse work experience spanning multiple industries. Gabriel currently holds the position of Vice President Quality Assurance at LTS Lohmann Therapie-Systeme AG since June 2023. Previously, from January 2021 to June 2023, they served as VP Quality Assurance at Eitan Medical. Gabriel also held positions such as Director of QA, Director of Research and V&V, and V&V Manager at Eitan Medical from 2015 to 2020.

In addition to their industry experience, Gabriel has been involved in ISO working groups as a participating member from September 2019 to June 2023. Prior to that, they worked at Aminolab Ltd. as the Head of Microbiology, responsible for a team of 22 people and the business aspects of the department from March 2014 to September 2015.

Gabriel also has experience in stem cell research, having served as the Head of a research group at Stem Cell Medicine from February 2012 to February 2014. Gabriel was responsible for day-to-day laboratory and personnel management, as well as the establishment of a clinical tissue bank. Furthermore, Gabriel worked as a Teaching Assistant at the College of Management Academic Studies from October 2010 to January 2014, where they assisted in teaching various courses related to biotechnology and biomedical management.

Prior to their industry experience, Gabriel worked as a Licensing Assistant at Yeda R&D, where they marketed Weizmann Institute technologies to potential companies. Gabriel also gained experience in the clinical trial field as the Head of the tissue-culture team at MultiGene Vascular Systems, working on a Phase I clinical trial at the University of Michigan and producing clinical-grade viruses.

Overall, Gabriel Zarbiv, PhD has held various roles within the field of quality assurance, research and development, microbiology, stem cell medicine, academia, technology transfer, and clinical trials.

Gabriel Zarbiv, PhD, has a strong educational background in the field of biotechnology engineering. Gabriel completed their Bachelor of Science (B.Sc) degree in Biotechnology Engineering from Technion - Israel Institute of Technology in 2003. Following this, they pursued their Master of Science (M.Sc) degree in the same field at Technion - Israel Institute of Technology from 2003 to 2005. Building on their previous studies, they then attended Weizmann Institute of Science, where they obtained their Doctor of Philosophy (PhD) degree in Biochemistry, specializing in their chosen field. Their PhD studies took place from 2007 to 2011 at the prestigious institute.